2. IL2Ra compared with placebo/no treatment: stratified meta‐analysis (cytomegalovirus disease, malignancy).
| Cytomegalovirus disease | Malignancy | |||||
| N | RR (95% CI) | P | N | RR (95% CI) | P | |
| Publication status | ||||||
| Abstract | 5 | 0.97 (0.65, 1.44) | 0.47 | 4 | 1.18 (0.15, 9.62) | 0.70 |
| Journal | 12 | 0.82 (0.69, 0.98) | 15 | 0.76 (0.41, 1.42) | ||
| ITT analysis | ||||||
| ITT used | 11 | 0.93 (0.73, 1.18) | 0.30 | 11 | 0.71 (0.31, 1.61) | 0.72 |
| No/ unclear | 6 | 0.78 (0.63, 0.97) | 8 | 0.89 (0.37, 2.10) | ||
| Risk of AR | ||||||
| Low | 8 | 0.82 (0.65, 1.05) | 0.47 | 9 | 0.70 (0.28, 1.81) | 0.82 |
| Mixed | 5 | 0.83 (0.66, 1.06) | 6 | 0.93 (0.41, 2.11) | ||
| High | 0 | No data | 0 | No data | ||
| Unclear | 4 | 1.02 (0.63, 1.65) | 4 | 0.22 (0.01, 5.99) | ||
| CNI | ||||||
| Cyclosporine | 15 | 0.88 (0.73, 1.06) | 0.34 | 16 | 0.73 (0.38, 1.40) | 0.43 |
| Tacrolimus | 1 | 5.00 (0.61, 41.3) | 2 | 0.06 (0.01, 5.84) | ||
| Unclear/mixed | 1 | 0.72 (0.53,0.99) | 1 | 1.66 (0.35, 7.94) | ||
| Antimetabolite | ||||||
| Azathioprine | 5 | 1.18 (0.84, 1.65) | 0.05 | 8 | 0.58 (0.20,1.72) | 0.81 |
| Mycophenolate | 7 | 0.78 (0.60, 1.02) | 7 | 1.10 (0.42, 2.87) | ||
| Unclear/mixed | 5 | 0.75 (0.58, 0.97) | 4 | 0.70 (0.18, 2.74) | ||
| IL2Ra | ||||||
| Basiliximab | 9 | 0.88 (0.71, 1.10) | 0.74 | 11 | 0.51 (0.25, 1.05) | 0.05 |
| Daclizumab | 6 | 0.81 (0.61, 1.08) | 7 | 1.81 (0.63, 5.20) | ||
| Other | 2 | 0.81 (0.10, 6.32) | 1 | 7.00 (0.38, 129.9) | ||
N = total number of studies reporting given outcome, RR = risk ratio, P = P for difference among strata, ITT = analysis by intention to treat principle, CNI= calcineurin inhibitor, IL2Ra= interleukin 2 receptor antibody